Inhibikase Therapeutics, Inc. (IKT) Adds Scott Wasserman to Board

Inhibikase Therapeutics, Inc. (IKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity WILMINGTON, Del., August 11, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-

Inhibikase Therapeutics (IKT) said it sold 25 million shares via an at-the-market facility to RA Capital Management, raising $50 million in gross proceeds. The company plans to use the funds, plus reserves, to support operations through topline data from Part B of its Phase 3 IMPROVE-PAH study for IKT-001, pending warrant exercise. Shares rose about 5% to $2.06.

Morgan Stanley kept Vir Biotechnology at Overweight, raising its price target to $28 from $25, citing a 105.2% upside from the Nov 9 close of $13.64. Recent analyst targets range from $22 to $25.

Michael Burry reduced his bearish Caterpillar (CAT) position by 75% after his put options quadrupled in value. CAT's stock fell 10% last week but rebounded 7.2% to $598.88. Q3 revenue rose 17% to $20.7B, with earnings up to $7.20 per share. CAT's Power & Energy division saw 18% sales growth, driven by data center demand.

Boeing plans to cut 2,500 jobs (5%) in its commercial airplanes division due to slower-than-expected production increases. The division, which makes the 737 Max, lost $697 million last quarter. Layoffs will begin in December, combining attrition and involuntary cuts. Boeing's stock is down 25% in 2026.

Freedom Broker downgraded Costco (COST) to hold, raising its price target to $1,050. The stock trades near its 52-week high, with October sales up 12.6% YoY. Analysts note premium valuation but positive operating model. Other firms have mixed outlooks, with price targets ranging from $1,050 to $1,250.